Ewelina Jarosz-Wójcik
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Research Subjects
Ewelina Jarosz-Wójcik has a total of 12 co-authors. Here are the top co-authors by number of shared publications:
- Dorota Drożdż
Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Krakow, Poland
2 shared publications - Monika Miklaszewska
Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Cracow, Poland
2 shared publications - Aleksandra Maria Molek
Student Research Group at Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Cracow, Poland
1 shared publication - Karina Madej-Świątkowska
Doctoral School of Medical and Health Sciences, Jagiellonian University Medical College
1 shared publication - Katarzyna Zachwieja
Department of Pediatric Nephrology and Hypertension, Jagiellonian University Medical College, Krakow, Poland
1 shared publication - Magdalena Błasiak
Department of Pediatric Nephrology and Hypertension, University Children's Hospital, Cracow, Poland
1 shared publication
Latest Publications
- Open Access
- 5 June 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (9) , 1153-1162
Impact of the COVID-19 pandemic on pediatric hemolytic uremic syndrome: Epidemiology, complications, and outcomes
Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is most commonly caused by infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Atypical HUS (aHUS) is associated with inappropriate activation of the alternative complement pathway caused by infections, including SARS-CoV-2, malignancies, medications, or other triggering factors in genetically predisposed individuals. Assessment of the impact of the COVID-19 pandemic on epidemiology, course, complications, and outcome of HUS in children in a single tertiary nephrological center in Poland. It is a retrospective study, in which a total number of 74 pediatric patients with HUS were analyzed, including 16 cases in 5-year period before the outbreak of the COVID-19 pandemic (HUS-5) and 58 cases in 5-year period after the outbreak of the pandemic (HUS+5). A more than 3.6-fold increase in HUS cases and a 7-fold higher incidence of STEC-HUS were reported in the HUS+5 population. Strokes and persistent neurological complications were observed only in this group. 91.9% of patients presented with abnormal renal ultrasound (USG) findings at admission, and these findings improved significantly more frequently in the HUS-5 (68.75% vs 25.9%, p = 0.002) group. Mortality did not differ significantly between the 2 analyzed groups and was 6.8% for the entire population. The COVID-19 pandemic has had a significant impact on the incidence of HUS in the pediatric population. SARS-CoV-2 infection most markedly increases the risk of neurological complications but does not affect overall mortality.
- 5 June 2026
- Published by Wroclaw Medical University in Advances in Clinical and Experimental Medicine
- Vol. 35 (9) , 1153-1162
Open AccessImpact of the COVID-19 pandemic on pediatric hemolytic uremic syndrome: Epidemiology, complications, and outcomes
Hemolytic-uremic syndrome (HUS) is a thrombotic microangiopathy that is most commonly caused by infection with Shiga toxin-producing Escherichia coli (STEC-HUS). Atypical HUS (aHUS) is associated with inappropriate activation of the alternative complement pathway caused by infections, including SARS-CoV-2, malignancies, medications, or other triggering factors in genetically predisposed individuals. Assessment of the impact of the COVID-19 pandemic on epidemiology, course, complications, and outcome of HUS in children in a single tertiary nephrological center in Poland. It is a retrospective study, in which a total number of 74 pediatric patients with HUS were analyzed, including 16 cases in 5-year period before the outbreak of the COVID-19 pandemic (HUS-5) and 58 cases in 5-year period after the outbreak of the pandemic (HUS+5). A more than 3.6-fold increase in HUS cases and a 7-fold higher incidence of STEC-HUS were reported in the HUS+5 population. Strokes and persistent neurological complications were observed only in this group. 91.9% of patients presented with abnormal renal ultrasound (USG) findings at admission, and these findings improved significantly more frequently in the HUS-5 (68.75% vs 25.9%, p = 0.002) group. Mortality did not differ significantly between the 2 analyzed groups and was 6.8% for the entire population. The COVID-19 pandemic has had a significant impact on the incidence of HUS in the pediatric population. SARS-CoV-2 infection most markedly increases the risk of neurological complications but does not affect overall mortality.
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Key technical aspects and vascular access safety in membrane-based therapeutic plasma exchange for the pediatric population
Introduction: Therapeutic plasma exchange (TPE) is a widely used extracorporeal blood purification procedure. While its principles are similar across age groups, the technical complexity and risks are heightened in pediatric patients due to unique technical considerations. This study assesses the safety regarding both technical and clinical complications of vascular access and filters of membrane technique TPE performed in a pediatric population at a single center.Material and methods: This retrospective cohort study reviewed charts of patients undergoing TPE at a level 3 referral center over 25 years.Results: The study involved 178 patients undergoing a total of 740 procedures during 214 sessions, predominantly using femoral vascular access. The median duration of the entire TPE sessions (treated as a surrogate for catheter lifespan) was 118.5 hours. Technical complications occurred in 20.8% of procedures (31.6% of events), while clinical complications occurred in 4.2% (4.7% of events). Technical complications were nearly five times more frequent than clinical complications, with technical events being 6.7 times more common. The proportion of patients experiencing clinical complications amounted to 15.2%. Logistic regression demonstrated that each additional day of catheter placement increased the probability of technical complications by 3%. Additionally, each year of patient age decreased the likelihood of clinical complications by 8.9%, while Fresh Frozen Plasma (FFP) supplementation within a session increased the probability of clinical complications by 21.6%.Conclusions: Prolonged catheter use increases technical events, while FFP supplementation elevates catheter-related clinical complication risk. Advancing patient age reduces the likelihood of clinical complications, underscoring age-specific safety considerations in pediatric TPE.
- 23 August 2025
- Published by Termedia Sp. z.o.o. in Archives of Medical Science
Key technical aspects and vascular access safety in membrane-based therapeutic plasma exchange for the pediatric population
Introduction: Therapeutic plasma exchange (TPE) is a widely used extracorporeal blood purification procedure. While its principles are similar across age groups, the technical complexity and risks are heightened in pediatric patients due to unique technical considerations. This study assesses the safety regarding both technical and clinical complications of vascular access and filters of membrane technique TPE performed in a pediatric population at a single center.Material and methods: This retrospective cohort study reviewed charts of patients undergoing TPE at a level 3 referral center over 25 years.Results: The study involved 178 patients undergoing a total of 740 procedures during 214 sessions, predominantly using femoral vascular access. The median duration of the entire TPE sessions (treated as a surrogate for catheter lifespan) was 118.5 hours. Technical complications occurred in 20.8% of procedures (31.6% of events), while clinical complications occurred in 4.2% (4.7% of events). Technical complications were nearly five times more frequent than clinical complications, with technical events being 6.7 times more common. The proportion of patients experiencing clinical complications amounted to 15.2%. Logistic regression demonstrated that each additional day of catheter placement increased the probability of technical complications by 3%. Additionally, each year of patient age decreased the likelihood of clinical complications by 8.9%, while Fresh Frozen Plasma (FFP) supplementation within a session increased the probability of clinical complications by 21.6%.Conclusions: Prolonged catheter use increases technical events, while FFP supplementation elevates catheter-related clinical complication risk. Advancing patient age reduces the likelihood of clinical complications, underscoring age-specific safety considerations in pediatric TPE.